Alan Boddy

Summary

Affiliation: University of Newcastle
Country: UK

Publications

  1. pmc Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer
    I Willits
    Northern Institute for Cancer Research, University of Newcastle, Newcastle upon Tyne NE2 4HH, UK
    Br J Cancer 92:1626-35. 2005
  2. pmc Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
    J Bray
    Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle upon Tyne, UK
    Br J Cancer 102:1003-9. 2010
  3. pmc Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours
    G J Veal
    Northern Institute for Cancer Research, University of Newcastle upon Tyne, Newcastle upon Tyne, UK
    Br J Cancer 96:725-31. 2007
  4. pmc Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - a study of the United Kingdom Children's Cancer Study Group
    G J Veal
    Northern Institute for Cancer Research, University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH, UK
    Br J Cancer 96:424-31. 2007
  5. pmc Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations
    A Azzabi
    Northern Institute for Cancer Research, University of Newcastle, Newcastle upon Tyne NE2 4HH, UK
    Br J Cancer 92:1006-12. 2005
  6. pmc Thiothymidine combined with UVA as a potential novel therapy for bladder cancer
    S W Pridgeon
    Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle NE2 4HH, UK
    Br J Cancer 104:1869-76. 2011
  7. ncbi request reprint Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer
    A V Boddy
    Cancer Research Unit, University of Newcastle, Newcastle upon Tyne, UK
    Cancer Chemother Pharmacol 48:15-21. 2001
  8. ncbi request reprint A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules
    Alan V Boddy
    Northern Institute for Cancer Research, University of Newcastle, UK
    Clin Cancer Res 11:7834-40. 2005
  9. ncbi request reprint Metabolism and pharmacokinetics of oxazaphosphorines
    A V Boddy
    Cancer Research Unit, Medical School, University of Newcastle upon Tyne, England
    Clin Pharmacokinet 38:291-304. 2000
  10. ncbi request reprint Dosing of cancer patients with low or absent renal function
    Alan Boddy
    Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne and Derby Hospitals NHS Trust, Derby, UK
    Therapie 62:117-20. 2007

Collaborators

Detail Information

Publications40

  1. pmc Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer
    I Willits
    Northern Institute for Cancer Research, University of Newcastle, Newcastle upon Tyne NE2 4HH, UK
    Br J Cancer 92:1626-35. 2005
    ..Fractionated dosing causes a greater degree of DNA damage, which may suggest a greater degree of efficacy, with a good correlation between pharmacokinetic and pharmacodynamic data...
  2. pmc Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
    J Bray
    Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle upon Tyne, UK
    Br J Cancer 102:1003-9. 2010
    ..It is not known whether this genetic variation has an impact on the efficacy or toxicity of AC therapy...
  3. pmc Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours
    G J Veal
    Northern Institute for Cancer Research, University of Newcastle upon Tyne, Newcastle upon Tyne, UK
    Br J Cancer 96:725-31. 2007
    ..Pharmacodynamic data suggest a strong correlation between carboplatin pharmacokinetics and the drug-target interaction...
  4. pmc Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - a study of the United Kingdom Children's Cancer Study Group
    G J Veal
    Northern Institute for Cancer Research, University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH, UK
    Br J Cancer 96:424-31. 2007
    ..d. 4.67+/-3.17 microM) higher than those of 13-cisRA (2.83+/-1.44 microM) in 16 out of 23 patients on day 14 of course 2. Extensive metabolism to 4-oxo-13-cisRA may influence pharmacological activity of 13-cisRA...
  5. pmc Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations
    A Azzabi
    Northern Institute for Cancer Research, University of Newcastle, Newcastle upon Tyne NE2 4HH, UK
    Br J Cancer 92:1006-12. 2005
    ..One patient remains alive and symptom-free at 4 years after treatment. Temozolomide and paclitaxel may be administered safely at clinically effective doses. Further evaluation of these combinations in melanoma is warranted...
  6. pmc Thiothymidine combined with UVA as a potential novel therapy for bladder cancer
    S W Pridgeon
    Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle NE2 4HH, UK
    Br J Cancer 104:1869-76. 2011
    ..Studies were performed to determine if the combination of S(4)TdR and UVA could be an effective treatment for bladder cancer...
  7. ncbi request reprint Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer
    A V Boddy
    Cancer Research Unit, University of Newcastle, Newcastle upon Tyne, UK
    Cancer Chemother Pharmacol 48:15-21. 2001
    ..To determine the effect on systemic pharmacology and clinical toxicity of dose and mode of administration of paclitaxel combined with carboplatin in the treatment of ovarian cancer...
  8. ncbi request reprint A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules
    Alan V Boddy
    Northern Institute for Cancer Research, University of Newcastle, UK
    Clin Cancer Res 11:7834-40. 2005
    ..To determine the safety, maximum tolerated dose, pharmacokinetics, and toxicities associated with administration of paclitaxel poliglumex (PPX, XYOTAX, Cell Therapeutics, Inc., Bresso, Italy) given on either 3-weekly or 2-weekly schedule...
  9. ncbi request reprint Metabolism and pharmacokinetics of oxazaphosphorines
    A V Boddy
    Cancer Research Unit, Medical School, University of Newcastle upon Tyne, England
    Clin Pharmacokinet 38:291-304. 2000
    ..Further advances in analytical and molecular pharmacological techniques may further optimise their use and allow rational design of more selective analogues...
  10. ncbi request reprint Dosing of cancer patients with low or absent renal function
    Alan Boddy
    Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne and Derby Hospitals NHS Trust, Derby, UK
    Therapie 62:117-20. 2007
  11. ncbi request reprint Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia
    Alan V Boddy
    Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom
    Clin Cancer Res 13:4164-9. 2007
    ..To investigate the potential use of accelerator mass spectrometry (AMS) in the study of the clinical pharmacology of imatinib...
  12. pmc Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy
    B Peng
    Department of Oncology, Medical School, The University of Newcastle upon Tyne, UK
    Br J Cancer 76:1466-73. 1997
    ..Intrinsic differences between the two complexes, primarily reactivity, probably explain the lower adduct levels observed after carboplatin treatment...
  13. pmc Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors
    Ruth Plummer
    Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom
    Clin Cancer Res 14:7917-23. 2008
    ..The article reports safety, efficacy, pharmacokinetic, and pharmacodynamic results of the first-in-class trial of a PARP inhibitor, AG014699, combined with temozolomide in adults with advanced malignancy...
  14. ncbi request reprint Pharmacokinetics and pharmacogenetics of 13-cis-retinoic acid in the treatment of neuroblastoma
    Gareth Veal
    Northern Institute for Cancer Research, Newcastle University, Framington Place, Newcastle upon Tyne, United Kingdom
    Therapie 62:91-3. 2007
    ....
  15. pmc Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo
    J L Armstrong
    Newcastle University, Northern Institute for Cancer Research, Paul O Gorman Building, Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK
    Br J Cancer 96:1675-83. 2007
    ..These data suggest considerable potential for CYP26 inhibitors in the future treatment of neuroblastoma with 13cisRA...
  16. ncbi request reprint Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy
    G J Veal
    Cancer Research Unit, University of Newcastle upon Tyne, Newcastle upon Tyne, NE2 4HH, United Kingdom
    Clin Cancer Res 7:2205-12. 2001
    ..These results imply that analysis of adducts in PBLs after incubation of pretreatment blood samples with cisplatin may be used to predict in vivo adduct levels, leukopenia, and, potentially, response to cisplatin therapy...
  17. pmc Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells
    J L Armstrong
    Northern Institute for Cancer Research, Paul O Gorman Building, Medical School, Framlington Place, University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH, UK
    Br J Cancer 92:696-704. 2005
    ..The response of neuroblastoma cells to R116010 was consistent with inhibition of CYP26, indicating that inhibition of RA metabolism may further optimise retinoid treatment in neuroblastoma...
  18. pmc Estimation of renal function and its potential impact on carboplatin dosing in children with cancer
    G Chinnaswamy
    Northern Institute for Cancer Research, University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH, UK
    Br J Cancer 99:894-9. 2008
    ..A standard methodology for estimating GFR should be followed to achieve uniform dosing in children with cancer...
  19. pmc A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer
    N Siddiqui
    Nothern Centre for Cancer Treatment, Newcastle General Hospital, Newcastle upon Tyne, UK
    Br J Cancer 75:287-94. 1997
    ..The results of this study, with only a small number of patients, need to be confirmed in future investigations...
  20. pmc A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin
    G J Veal
    Cancer Research Unit, Medical School, University of Newcastle upon Tyne, UK
    Br J Cancer 84:1029-35. 2001
    ..Results from this phase I study indicate that high doses of liposomal cisplatin can safely be given to patients, but further studies are required to address the issue of reformulation of liposomally bound cisplatin...
  21. pmc Estimation of glomerular filtration rate in cancer patients
    J G Wright
    Department of Oncology, University of Newcastle, UK
    Br J Cancer 84:452-9. 2001
    ..The formulae developed here can be used to provide reliable estimates of GFR, particularly in regard to targeted dosing of carboplatin...
  22. pmc Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxel
    A N Hughes
    Medical School, University of Newcastle upon Tyne, Department of Medical Oncology, Newcastle General Hospital, UK
    Br J Cancer 82:1519-27. 2000
    ..Studies in vitro suggest some synergy, however, due to a pharmacokinetic interaction, paclitaxel doses should be reduced when administered during nolatrexed infusion...
  23. ncbi request reprint Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)
    M A Batey
    Department of Oncology, Medical School, University of Newcastle, NE2 4HH, Newcastle upon Tyne, UK
    Eur J Cancer 38:1081-9. 2002
    ..For all three drugs, interoccasion variability was of the same order (20-40%) as that between individuals, suggesting a limited potential for dose-optimisation of this regimen...
  24. pmc Estimation of glomerular filtration rate in paediatric cancer patients using 51CR-EDTA population pharmacokinetics
    M Cole
    Northern Institute for Cancer Research, Medical School, University of Newcastle, Newcastle upon Tyne NE2 4HH, UK
    Br J Cancer 90:60-4. 2004
    ..7 and 20.0%. These simple additive models provide a more rationale approach than the use of complex formulae, involving additional parameters, to predict renal function...
  25. ncbi request reprint Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma
    Andy Hughes
    Department of Medical Oncology, Northern Centre for Cancer Treatment, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne NE4 6BE, United Kingdom
    J Clin Oncol 20:3533-44. 2002
    ..We assessed toxicities and explored the activity of the drug combination exclusively in patients with malignant pleural mesothelioma (MPM). The pharmacokinetics of both agents was investigated...
  26. ncbi request reprint Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group
    Markus Joerger
    Department of Pharmacy and Pharmacology, Slotervaart Hospital The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Clin Cancer Res 13:6410-8. 2007
    ..05 to 0.2 micromol/L (t(C > 0.05-0.2)) predicts neutropenia. The objective of this study was to build a population pharmacokinetic-pharmacodynamic model of paclitaxel/carboplatin in ovarian cancer patients...
  27. ncbi request reprint Population pharmacokinetic investigation of actinomycin-D in children and young adults
    John T Mondick
    Division of Clinical Pharmacology and Therapeutics, The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    J Clin Pharmacol 48:35-42. 2008
    ..Relationships between pharmacokinetics and toxicity will be examined in future prospective studies in which children less than 1 year old will be enrolled...
  28. pmc Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide
    Huw D Thomas
    Cancer Research Unit, Medical School, University of Newcastle, Newcastle General Hospital, Newcastle upon Tyne NE2 4HH, UK
    Br J Clin Pharmacol 53:83-91. 2002
    ..In a randomized cross-over study, the potential interaction between the two platinum drugs and the metabolism of etoposide was explored. In vitro investigations using human liver microsomes were also performed...
  29. ncbi request reprint Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cells
    Gareth J Veal
    Cancer Research Unit, Medical School, University of Newcastle upon Tyne, NE2 4HH, Newcastle upon Tyne, UK
    Biochem Pharmacol 63:207-15. 2002
    ..In summary, these results indicate either an intracellular conversion of 13-cis RA to ATRA or a selective uptake of ATRA and suggest that this may mediate the differential activity of 13-cis RA in neuroblastoma cell subtypes...
  30. ncbi request reprint Chemotherapy individualization
    Gareth J Veal
    Northern Institute for Cancer Research, Cancer Research Unit, Medical School, University of Newcastle upon Tyne, Newcastle upon Tyne, NE2 4HH, United Kingdom
    Invest New Drugs 21:149-56. 2003
    ....
  31. ncbi request reprint Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry
    Gareth J Veal
    Northern Institute for Cancer Research, University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH, UK
    J Chromatogr B Analyt Technol Biomed Life Sci 795:237-43. 2003
    ..8%, respectively. Accuracy data showed relative errors of 2.0-16.4 and 10.4-15.2% for intra-assay (n=10) and inter-assay (n=7) experiments, respectively. Initial results of actinomycin D pharmacokinetics in paediatric patients are shown...
  32. ncbi request reprint NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism
    David Jamieson
    Northern Institute for Cancer Research, Medical School, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom
    Clin Cancer Res 13:1584-90. 2007
    ..The NQO activity of ovarian and bladder tumors was determined and the effect of NQO polymorphisms on NQO activity was investigated...
  33. ncbi request reprint Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1
    E Ruth Plummer
    Northern Institute for Cancer Research, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom
    Clin Cancer Res 11:3402-9. 2005
    ..The current study was done to define the effect of temozolomide on DNA integrity and relevant repair enzymes as a prelude to a phase I trial of the combination of temozolomide with a PARP inhibitor...
  34. ncbi request reprint Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study
    Gareth J Veal
    Northern Institute for Cancer Research, University of Newcastle upon Tyne, UK
    Clin Cancer Res 11:5893-9. 2005
    ..Despite concerns over the incidence of toxicity, little is known about the pharmacology of dactinomycin. A study was done to investigate dactinomycin pharmacokinetics in children...
  35. ncbi request reprint 2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337
    Paula Wells
    Imperial College School of Medicine, Hammersmith Hospital, London, UK
    J Natl Cancer Inst 95:675-82. 2003
    ..We investigated the use of 2-[11C]thymidine positron emission tomography (PET) to measure thymidine salvage kinetics in vivo in humans...
  36. pmc Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy
    Alan V Boddy
    Northern Institute for Cancer Research, Medical School, University of Newcastle, Newcastle upon Tyne, UK
    Br J Clin Pharmacol 62:27-34. 2006
    ..Extending the use of these approaches to pharmacodynamic end-points, together with the application of population-based modelling techniques, offers the potential to develop truly individualized therapy in the future...
  37. ncbi request reprint Biliary excretion of etoposide in children with cancer
    Gareth J Veal
    Northern Institute for Cancer Research, Paul O Gorman Building, Medical School, University of Newcastle upon Tyne, UK
    Cancer Chemother Pharmacol 58:415-7. 2006
    ..These unusual cases provided an opportunity to investigate the biliary clearance of etoposide by determining etoposide concentrations in bile and plasma samples obtained during chemotherapy...
  38. ncbi request reprint Cyclophosphamide metabolism in children with non-Hodgkin's lymphoma
    S Murray Yule
    Department of Child Health, Yorkhill National Health Service Trust, Glasgow, United Kongdom
    Clin Cancer Res 10:455-60. 2004
    ..The purpose of our study was to determine whether variation in cyclophosphamide metabolism influences the incidence of recurrence among children receiving chemotherapy for B-cell non-Hodgkin's lymphoma...
  39. ncbi request reprint Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy
    Gareth J Veal
    Northern Institute for Cancer Research, University of Newcastle upon Tyne, NE2 4HH, Newcastle upon Tyne, UK
    Cancer Chemother Pharmacol 54:295-300. 2004
    ....
  40. ncbi request reprint Potential clinical impact of taking multiple blood samples for research studies in paediatric oncology: how much do we really know?
    Michael Cole
    Northern Institute for Cancer Research, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom
    Pediatr Blood Cancer 46:723-7. 2006
    ..Research involving children with cancer should be limited to those studies addressing key scientific questions and should be designed to limit both the number and volume of blood samples required...